$XBI $89.44 | -2.62%
Covid Updates
$NVAX -1.1% Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain source
Pipeline Updates
$UBX -9.4% UNITY BIOTECHNOLOGY ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY AND FOCUS ON KEY OPHTHALMOLOGY PROGRAMS source
$OPK +5.2% RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP source
$CPRX -2.3% Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid source
$URGN -3.7% UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer source
$LPCN -2.0% LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO® source
$MRNS -1.6% Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update source
$KOD +3.0% Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema source
Business Updates
$NTLA -0.9% Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics source
Posted by JM
תגובות